4-PPBP maleate

Cat. No.:	HY-101043	
CAS No.:	201216-39-9	
Molecular Formula:	$C_{25}H_{31}NO_{4}$	
Molecular Weight:	409.52	Ň,
Target:	Sigma Receptor; iGluR	HO _N _c O _c
Pathway:	Neuronal Signaling; Membrane Transporter/Ion Channel	
Storage:	4°C, sealed storage, away from moisture	ОН
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4419 mL	12.2094 mL	24.4188 mL
		5 mM	0.4884 mL	2.4419 mL	4.8838 mL
		10 mM	0.2442 mL	1.2209 mL	2.4419 mL

BIOLOGICAL ACTIV	ТТҮ				
Description	4-PPBP maleate is a potent σ 1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection ^{[1][2][3]} .				
In Vitro	4-PPBP maleate elicits ERK1/2 phosphorylation in primary neurons^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
In Vivo	4-PPBP maleate (1 μmol/kg; i.v.) decreases brain injury after transient focal ischemia in rats^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
	Animal Model:	Male rats weighing 300 to 385 g (Transient focal ischemia model) $^{[2]}$			
	Dosage:	1 μmol/kg			
	Administration:	Per hour by continuous intravenous infusion starting 1 hour after the initiation of ischemia and continuing through 22 hours of reperfusion.			



Result:

REFERENCES

[1]. Whittemore ER, et al. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. J Pharmacol Exp Ther. 1997;282(1):326-338.

[2]. Takahashi H, et al. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats. Stroke. 1996;27(11):2120-2123.

[3]. Tan F, et al. The σ 1 receptor agonist 4-PPBP elicits ERK1/2 phosphorylation in primary neurons: a possible mechanism of neuroprotective action. Neuropharmacology. 2010;59(6):416-424.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA